Epigenetic Changes in Psychotherapy of Adolescents With Borderline Personality Pathology
NCT ID: NCT04095546
Last Updated: 2022-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2022-04-30
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neuropsychiatric Mechanisms of Change in Mentalization Based Treatment of Borderline Personality Disorder (MENTAB)
NCT01720953
Effects of Motive-Oriented Therapeutic Relationship in the Early-Phase Treatment of Borderline Personality Disorder
NCT01896024
MBT-early: a Single Case Experimental Design
NCT06212024
Internal Family Systems Therapy for Borderline Personality Disorder
NCT07342907
Mentalization-Based Therapy to Prevent Suicidal Behavior in Adolescents With Bipolar Disorder
NCT02129790
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
routine psychotherapy for Borderline Personality Disorder (BPD)
Routine psychotherapy as treatment for patients with Borderline Personality Disorder
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* psychotic disorders
* pervasive developmental disorders
* severe somatic or neurological disorders
* severe and persistent substance addiction
* elevated risk for complications related to blood sampling
14 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Leading House for the Latin American Region (Seed Money Grant SMG 1730)
UNKNOWN
University Hospital, Basel, Switzerland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ronan Zimmermann, PhD
Role: PRINCIPAL_INVESTIGATOR
Kinder- und Jugendpsychiatrische Klinik/Universitäre Psychiatrische Klinken Basel (UPK)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-00658; pk19Zimmermann
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.